Autotaxin (ATX) as a Marker for Breast Cancer

Summary

Breast cancer is the leading cause of cancer death in women worldwide. According to the GLOBOCAN 2018 worldwide estimates of cancer incidence and mortality, in 2018, about 2,088,849 new cases were diagnosed and approximately 626,679 women were predicted to die from the disease . It is the leading cause of cancer related mortality, representing15% of deaths per year worldwide .

Conditions

• Breast Cancer

Interventions

DIAGNOSTIC_TEST

Serum Autotaxin

Marker

RADIATION

chest x-ray

chest x- ray will be done for the study group

DIAGNOSTIC_TEST

Breast ultrasound or mammography

Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer

DIAGNOSTIC_TEST

Histopathological examination of breast mass specimens

by True cut or fine needle aspiration cytology

RADIATION

Magnetic Resonance Imaging ( MRI) and Bone scan

will be done for the study group

DIAGNOSTIC_TEST

Peripheral haemogram

blood sample will be taken from the patients

DIAGNOSTIC_TEST

Renal and liver functions

to exclude any other morbidity

DIAGNOSTIC_TEST

Prothrombin time and concentration

blood sample will be taken from the patients

DIAGNOSTIC_TEST

Cancer Antigen 15-3 (CA15-3).

will be done for the 2 groups

OTHER

Full medical history

full medical history will be taken from all patients

OTHER

Full clinical examination

full clinical examination will be done for the patients

Sponsors & Collaborators

• Assiut University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

69 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-05-01

Primary Completion

2022-05-01

Completion

2022-11-01